ARTICLE | Clinical News
CHMP recommends AbbVie's HCV combo Maviret
June 30, 2017 7:00 PM UTC
EMA’s CHMP recommended approval of an MAA from AbbVie Inc. (NYSE:ABBV) for Maviret glecaprevir/pibrentasvir to treat chronic HCV infection in adults. Maviret is under Priority Review by FDA...